Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the third quarter ended September 30, 2022.
Related news for (HOWL)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/22/25 05:00 PM
- MoBot alert highlights: NASDAQ: LIMN, NASDAQ: SLE, NYSE: BFLY, NASDAQ: SLNH, NASDAQ: HOWL (09/22/25 04:00 PM)
- MoBot alert highlights: NASDAQ: KITT, NASDAQ: VUZI, NASDAQ: HOWL, NASDAQ: BETRW, NASDAQ: KOD (09/22/25 01:00 PM)
- Werewolf Therapeutics to Participate in the BIO International Convention
- Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update